These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 19679402

  • 1. In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
    Dahle J, Krogh C, Melhus KB, Borrebaek J, Larsen RH, Kvinnsland Y.
    Int J Radiat Oncol Biol Phys; 2009 Nov 01; 75(3):886-95. PubMed ID: 19679402
    [Abstract] [Full Text] [Related]

  • 2. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
    Heyerdahl H, Krogh C, Borrebæk J, Larsen Å, Dahle J.
    Int J Radiat Oncol Biol Phys; 2011 Feb 01; 79(2):563-70. PubMed ID: 21195878
    [Abstract] [Full Text] [Related]

  • 3. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
    Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH.
    Nucl Med Biol; 2006 Feb 01; 33(2):271-9. PubMed ID: 16546683
    [Abstract] [Full Text] [Related]

  • 4. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
    Dahle J, Bruland OS, Larsen RH.
    Int J Radiat Oncol Biol Phys; 2008 Sep 01; 72(1):186-92. PubMed ID: 18722269
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.
    J Nucl Med; 2005 Nov 01; 46(11):1907-15. PubMed ID: 16269606
    [Abstract] [Full Text] [Related]

  • 6. Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation.
    Aurlien E, Kvinnsland Y, Larsen RH, Bruland ØS.
    Int J Radiat Biol; 2002 Feb 01; 78(2):133-42. PubMed ID: 11779363
    [Abstract] [Full Text] [Related]

  • 7. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
    Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH.
    Blood; 2007 Sep 15; 110(6):2049-56. PubMed ID: 17536011
    [Abstract] [Full Text] [Related]

  • 8. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis.
    Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL.
    Radiat Res; 1992 May 15; 130(2):220-6. PubMed ID: 1574578
    [Abstract] [Full Text] [Related]

  • 9. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.
    Leuk Res; 2006 May 15; 30(5):625-31. PubMed ID: 16289746
    [Abstract] [Full Text] [Related]

  • 10. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.
    J Nucl Med; 2005 Apr 15; 46(4):642-51. PubMed ID: 15809487
    [Abstract] [Full Text] [Related]

  • 11. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
    DeNardo GL, Tobin E, Chan K, Bradt BM, DeNardo SJ.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
    [Abstract] [Full Text] [Related]

  • 12. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
    Abbas N, Bruland ØS, Brevik EM, Dahle J.
    Nucl Med Commun; 2012 Aug 01; 33(8):838-47. PubMed ID: 22643311
    [Abstract] [Full Text] [Related]

  • 13. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Nowakowski GS, Witzig TE.
    Clin Adv Hematol Oncol; 2006 Mar 01; 4(3):225-31. PubMed ID: 16728934
    [Abstract] [Full Text] [Related]

  • 14. Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.
    Aurlien E, Larsen RH, Kvalheim G, Bruland OS.
    Br J Cancer; 2000 Nov 01; 83(10):1375-9. PubMed ID: 11044364
    [Abstract] [Full Text] [Related]

  • 15. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
    Michel RB, Andrews PM, Rosario AV, Goldenberg DM, Mattes MJ.
    Nucl Med Biol; 2005 Apr 01; 32(3):269-78. PubMed ID: 15820762
    [Abstract] [Full Text] [Related]

  • 16. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab.
    Kapadia NS, Engles JM, Wahl RL.
    J Nucl Med; 2008 Apr 01; 49(4):674-8. PubMed ID: 18344431
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, Atcher RW.
    Nucl Med Biol; 2007 Feb 01; 34(2):185-93. PubMed ID: 17307126
    [Abstract] [Full Text] [Related]

  • 18. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
    Thakral P, Singla S, Yadav MP, Vasisht A, Sharma A, Gupta SK, Bal CS, Snehlata, Malhotra A.
    Indian J Med Res; 2014 Apr 01; 139(4):544-54. PubMed ID: 24927340
    [Abstract] [Full Text] [Related]

  • 19. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
    Yadav MP, Singla S, Thakral P, Ballal S, Bal C.
    Nucl Med Commun; 2016 Jul 01; 37(7):735-42. PubMed ID: 26974315
    [Abstract] [Full Text] [Related]

  • 20. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    Nucl Med Biol; 2006 Nov 01; 33(8):1065-72. PubMed ID: 17127181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.